Insider Trading Activity Following Supernus‑Indivior Merger
The 2 November 2026 filing under the Securities Exchange Act of 1934 discloses a series of sell‑type transactions by key insiders at Supernus Pharmaceuticals following the completion of its merger with Indivior. The exchange of Supernus common stock for the newly‑renamed Supernus, Inc. common stock at a conversion ratio of 1.5401 shares per former share has altered the ownership structure and prompted a number of significant divestitures.
1. Transaction Summary
| Owner | Transaction Type | Shares | Security | Notes |
|---|---|---|---|---|
| GEMAYEL GEORGES | Sell | 27 277 | Common Stock | Executed at $28.15 closing price, no cash consideration beyond a fractional adjustment |
| Sell | 2 989 | Restricted Stock Unit | – | |
| Sell | 6 036 | Director Stock Option (Right to Buy) | – | |
| Sell | 8 613 | Director Stock Option (Right to Buy) | – | |
| Sell | 12 427 | Director Stock Option (Right to Buy) | – | |
| Sell | 9 305 | Director Stock Option (Right to Buy) | – | |
| Sell | 7 365 | Director Stock Option (Right to Buy) | – | |
| Sell | 6 847 | Director Stock Option (Right to Buy) | – | |
| Sell | 6 293 | Director Stock Option (Right to Buy) | – | |
| Sell | 8 252 | Director Stock Option (Right to Buy) | – | |
| Sell | 7 296 | Director Stock Option (Right to Buy) | – | |
| Sell | 4 977 | Director Stock Option (Right to Buy) | – | |
| HORICH WILLIAM TODD (SVP, Commercial Operations) | Sell | 100 000 | Restricted Stock Unit | – |
| Sell | 5 000 | Performance Share Unit | – | |
| Sell | 3 500 | Performance Share Unit | – | |
| Sell | 6 250 | Restricted Stock Unit | – | |
| Sell | 2 500 | Restricted Stock Unit | – | |
| Sell | 3 375 | Restricted Stock Unit | – | |
| Sell | 3 000 | Restricted Stock Unit | – | |
| Sell | 13 000 | Employee Stock Option (Right to Buy) | – | |
| Sell | 14 000 | Employee Stock Option (Right to Buy) | – | |
| Sell | 17 000 | Employee Stock Option (Right to Buy) | – | |
| Sell | 18 000 | Employee Stock Option (Right to Buy) | – | |
| Sell | 20 000 | Employee Stock Option (Right to Buy) | – | |
| Sell | 25 000 | Employee Stock Option (Right to Buy) | – | |
| Sell | 20 000 | Employee Stock Option (Right to Buy) | – | |
| Sell | 13 500 | Employee Stock Option (Right to Buy) | – | |
| KHAATAR JACK A. (President, CEO) | Sell | 1 258 351 | Common Stock | – |
| Sell | 958 100 | Common Stock | – | |
| Sell | 400 000 | Restricted Stock Unit | – | |
| Sell | 19 320 | Performance Share Unit | – | |
| Sell | 169 147 | Performance Share Unit | – | |
| Sell | 204 966 | Performance Share Unit | – | |
| Sell | 250 000 | Employee Stock Option (Right to Buy) | – | |
| Sell | 300 000 | Employee Stock Option (Right to Buy) | – | |
| Sell | 281 250 | Employee Stock Option (Right to Buy) | – | |
| Sell | 200 000 | Employee Stock Option (Right to Buy) | – | |
| Sell | 250 000 | Employee Stock Option (Right to Buy) | – | |
| Sell | 280 000 | Employee Stock Option (Right to Buy) | – | |
| Sell | 322 000 | Employee Stock Option (Right to Buy) | – | |
| Sell | 331 660 | Employee Stock Option (Right to Buy) | – | |
| Sell | 341 610 | Employee Stock Option (Right to Buy) | – | |
| DEC TIMOTHY C. (Senior Vice‑President & CFO) | Sell | 9 129 | Common Stock | – |
| Sell | 70 000 | Restricted Stock Unit | – | |
| Sell | 3 750 | Performance Share Unit | – | |
| Sell | 3 500 | Performance Share Unit | – | |
| Sell | 2 500 | Restricted Stock Unit | – | |
| Sell | 6 000 | Restricted Stock Unit | – | |
| Sell | 3 375 | Restricted Stock Unit | – | |
| Sell | 3 000 | Restricted Stock Unit | – | |
| Sell | 85 000 | Employee Stock Option (Right to Buy) | – | |
| Sell | 25 000 | Employee Stock Option (Right to Buy) | – | |
| Sell | 40 000 | Employee Stock Option (Right to Buy) | – | |
| Sell | 50 000 | Employee Stock Option (Right to Buy) | – | |
| Sell | 17 500 | Employee Stock Option (Right to Buy) | – | |
| Sell | 40 000 | Employee Stock Option (Right to Buy) | – | |
| Other Executives | – | – | – | Similar patterns of restricted units, options, and common stock sales recorded for senior directors, C‑suite officers, and other key stakeholders |
Key Observation: The volume of sales from the President/CEO and other senior executives is markedly higher than that of other insiders. The majority of these transactions involve common shares and restricted units, with a smaller proportion in performance‑share or employee‑option instruments.
2. Market Dynamics Post‑Merger
2.1. Immediate Stock Performance
- Weekly Gain: 20.56 % since the merger announcement, indicating robust investor confidence in the combined entity.
- Social‑Media Sentiment: +39, a bullish score that aligns with the positive price trend.
2.2. Competitive Positioning
- Product Portfolio: The merger brings together Supernus’s neurological therapeutics with Indivior’s specialty drug platform, creating a complementary pipeline that addresses unmet needs in addiction, sleep, and mental health.
- Geographic Reach: Expanded distribution channels in North America and Europe, positioning the company to capture emerging markets for neurology drugs.
2.3. Economic Factors
- Valuation Multiples: Current price-to-earnings and enterprise‑value multiples remain within the upper quartile for specialty pharma, reflecting market optimism.
- Regulatory Environment: Ongoing approvals for key indications may further enhance earnings potential, but any delay could exert downward pressure.
3. Investor Implications
- Insider Sell Signals:
- The large block sales by senior executives could be interpreted as a liquidity event tied to personal tax planning or portfolio rebalancing.
- The absence of cash consideration suggests a strategic realignment rather than distress.
- Potential Dilution Risks:
- While the merger involved a conversion ratio that increases shares outstanding, the current transaction volume does not immediately threaten dilution, but continuous selling may erode shareholder confidence.
- Future Outlook:
- Investors should monitor subsequent 13F filings and periodic reports for signs of renewed insider buying, which would reinforce confidence in the merged entity’s long‑term prospects.
- Any sustained selling trend, especially of performance‑share units tied to milestones, might signal concerns about achieving projected targets.
4. Conclusion
The insider activity following the completion of the Supernus‑Indivior merger reflects a pattern of liquidity management and strategic repositioning among senior executives. While the sizeable sell volumes—particularly from the President/CEO—require close observation, the market’s strong performance and bullish sentiment suggest that the broader investor base remains confident in the merged company’s growth trajectory. Continuous monitoring of insider transactions, coupled with an assessment of regulatory milestones and financial results, will provide the clearest indicators of the company’s future direction.
